Agilent Signs Agreement with Ambry Genetics

Agilent Technologies Inc. and Ambry Genetics have announced an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services.

“Ambry is intensely focused on delivering the highest quality results for exome sequencing for all of our clients and customers,” said Ardy Arianpour, vice president of Business Development at Ambry Genetics.

Arianpour continued, “With Agilent Technologies we have found the ideal partner we can count on in bringing our exome sequencing to market with scalability and speed. With Agilent’s SureSelect, Ambry Genetics is offering whole exome capture services for cancer markers, drug response and Mendelian disease gene discovery. Ambry’s exome sequencing services deliver state of the art bioinformatics which include variant filtering, annotation and interpretation of candidate mutations.”

“Agilent is very excited to partner with Ambry for their exome sequencing needs,” said Kathleen Shelton, Agilent senior marketing director, Genomics.

Shelton continued, “We believe the quality and consistency SureSelect brings closely complements the level of service provided by Ambry and expected by their customers.”

The SureSelect portfolio provides a complete and customizable target enrichment platform.

Since it was introduced in 2009, SureSelect has been instrumental in more than 160 published studies covering research into a wide range of heritable disorders and complex diseases.

There are now more than 21 products in the SureSelect portfolio, including a full range of catalog and custom products.

The SureSelect platform is fully flexible and can be used to enrich targets of interest from less than 20 Kb to more than 100 Mb using eArray, a free online design tool.